Personalized medicine in diabetes: the role of ‘omics’ and biomarkers

Metformin and the gastrointestinal tract

(2016) Laura J. McCreight et al.   DIABETOLOGIA

Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine

(2015) R Kaddurah-Daouk et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM ), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance

(2015) P. J. Connelly et al.   DIABETIC MEDICINE

Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes

(2015) T. Dujic et al.   DIABETIC MEDICINE

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

(2015) Kristoffer Forslund et al.   NATURE

Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study

(2014) Tanja Dujic et al.   DIABETES

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

RS11212617 is associated with metformin treatment response in type 2 diabetes in Shanghai local Chinese population

(2014) Y. Zhou et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis

(2014) Kaixin Zhou et al.   Lancet Diabetes & Endocrinology

Cometabolism of Microbes and Host: Implications for Drug Metabolism and Drug-Induced Toxicity

(2013) H Li et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts

(2012) N. van Leeuwen et al.   DIABETOLOGIA

Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia

(2011) Andreas Holstein et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept

(2011) R Kaddurah-Daouk et al.   Translational Psychiatry

Maturity-onset diabetes of the young (MODY): how many cases are we missing?

(2010) B. M. Shields et al.   DIABETOLOGIA

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

(2010) Kaixin Zhou et al.   NATURE GENETICS

Loss-of-Function CYP2C9 Variants Improve Therapeutic Response to Sulfonylureas in Type 2 Diabetes: A Go-DARTS Study

(2009) K Zhou et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Presence ofCYP2C9*3allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas

(2009) Georgia Ragia et al.   PHARMACOGENOMICS